HEADER ANTIMICROBIAL PROTEIN 25-SEP-25 9WXK TITLE LINEAR FRAGMENT OF LYCOSIN9I WITH ANTI-MRSA ACTIVITY COMPND MOL_ID: 1; COMPND 2 MOLECULE: LYCOSIN 9I 3K; COMPND 3 CHAIN: A; COMPND 4 ENGINEERED: YES; COMPND 5 OTHER_DETAILS: THE FRAGMENT OF LYCOSIN 9I WITH AMIDATED C-TERMINUS SOURCE MOL_ID: 1; SOURCE 2 SYNTHETIC: YES; SOURCE 3 ORGANISM_SCIENTIFIC: LYCOSA ERYTHROGNATHA; SOURCE 4 ORGANISM_TAXID: 332789 KEYWDS ANTIMICROBIAL PROTEIN, AMP, LINEAR PEPTIDE, SPIDER TOXIN, ALPHA- KEYWDS 2 HELICAL PEPTIDE, MRSA EXPDTA SOLUTION NMR NUMMDL 20 AUTHOR P.A.MIRONOV,P.V.DUBOVSKII,Z.O.SHENKAREV REVDAT 1 21-JAN-26 9WXK 0 JRNL AUTH P.A.MIRONOV,A.A.BARANOVA,V.A.ALFEROVA,N.S.EGOROVA, JRNL AUTH 2 A.A.IGNATOVA,A.V.FEOFANOV,Z.O.SHENKAREV,P.V.DUBOVSKII JRNL TITL NMR UNVEILS ACTIVITY MECHANISM OF LINEAR SPIDER VENOM JRNL TITL 2 PEPTIDE FRAGMENTS SELECTED BY NEURAL NETWORKS AGAINST JRNL TITL 3 STAPHYLOCOCCI INCLUDING MRSA. JRNL REF PHARMACEUTICS V. 17 2025 JRNL REFN ESSN 1999-4923 JRNL PMID 41471040 JRNL DOI 10.3390/PHARMACEUTICS17121526 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CYANA 3.98.13 REMARK 3 AUTHORS : GUNTERT, MUMENTHALER AND WUTHRICH REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 9WXK COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 26-SEP-25. REMARK 100 THE DEPOSITION ID IS D_1300064054. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 318 REMARK 210 PH : 4.5 REMARK 210 IONIC STRENGTH : 0.01 REMARK 210 PRESSURE : AMBIENT PA REMARK 210 SAMPLE CONTENTS : 0.12 MM LYCOSIN 9I IN LPPG REMARK 210 MICELLE, 16.8 MM LPPG, 5 % [U-99% REMARK 210 2H] D2O, 95% H2O/5% D2O REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 2D 1H-1H NOESY; 2D 1H-1H TOCSY; REMARK 210 2D 1H-13C HSQC ALIPHATIC; 2D 1H- REMARK 210 15N HSQC REMARK 210 SPECTROMETER FIELD STRENGTH : 700 MHZ; 800 MHZ REMARK 210 SPECTROMETER MODEL : AVANCE III REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : CYANA 3.98.13, TOPSPIN 3.5, CARA REMARK 210 METHOD USED : SIMULATED ANNEALING REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 200 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 20 REMARK 210 CONFORMERS, SELECTION CRITERIA : STRUCTURES WITH THE LEAST REMARK 210 RESTRAINT VIOLATIONS REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: NULL REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 MET A 6 -33.50 -179.70 REMARK 500 2 MET A 6 -33.29 179.92 REMARK 500 3 MET A 6 -33.20 179.88 REMARK 500 4 MET A 6 -33.33 179.97 REMARK 500 5 MET A 6 -33.30 -179.99 REMARK 500 6 MET A 6 -33.25 179.93 REMARK 500 7 MET A 6 -33.19 -179.95 REMARK 500 8 MET A 6 -33.33 -179.97 REMARK 500 9 MET A 6 -33.24 179.98 REMARK 500 10 MET A 6 -33.25 -179.97 REMARK 500 11 MET A 6 -33.21 -180.00 REMARK 500 12 MET A 6 -33.20 179.89 REMARK 500 13 MET A 6 -33.13 -179.99 REMARK 500 14 MET A 6 -33.24 -179.90 REMARK 500 15 MET A 6 -33.22 179.95 REMARK 500 16 MET A 6 -33.16 179.96 REMARK 500 17 MET A 6 -33.21 179.96 REMARK 500 18 MET A 6 -33.13 179.93 REMARK 500 19 MET A 6 -33.27 179.95 REMARK 500 20 MET A 6 -33.21 -179.94 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 36788 RELATED DB: BMRB REMARK 900 LINEAR FRAGMENT OF LYCOSIN9I WITH ANTI-MRSA ACTIVITY DBREF1 9WXK A 1 13 UNP A0A8D8EPN3_9ARAC DBREF2 9WXK A A0A8D8EPN3 11 23 SEQADV 9WXK NH2 A 14 UNP A0A8D8EPN AMIDATION SEQRES 1 A 14 ILE TRP LEU SER LEU MET LYS PHE ALA GLY LYS HIS LEU SEQRES 2 A 14 NH2 HET NH2 A 14 3 HETNAM NH2 AMINO GROUP FORMUL 1 NH2 H2 N HELIX 1 AA1 LYS A 7 LEU A 13 1 7 LINK C LEU A 13 N NH2 A 14 1555 1555 1.33 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000 MODEL 1 ENDMDL MODEL 2 ENDMDL MODEL 3 ENDMDL MODEL 4 ENDMDL MODEL 5 ENDMDL MODEL 6 ENDMDL MODEL 7 ENDMDL MODEL 8 ENDMDL MODEL 9 ENDMDL MODEL 10 ENDMDL MODEL 11 ENDMDL MODEL 12 ENDMDL MODEL 13 ENDMDL MODEL 14 ENDMDL MODEL 15 ENDMDL MODEL 16 ENDMDL MODEL 17 ENDMDL MODEL 18 ENDMDL MODEL 19 ENDMDL MODEL 20 ENDMDL CONECT 210 227 CONECT 227 210 228 229 CONECT 228 227 CONECT 229 227 MASTER 111 0 1 1 0 0 0 6 109 1 4 2 END